Vimarsana
Biggest News Aggregation in the World

Page 3 - Clinical Laboratory Evaluation Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Laboratory Evaluation Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Laboratory Evaluation Program Today - Breaking & Trending Today

FDA defends lab test rule, as critics fear industry upheaval - Vimarsana News

FDA defends lab test rule, as critics fear industry upheaval

BioPharma

FDA Brings Lab Tests Under Its Oversight - Vimarsana News

FDA Brings Lab Tests Under Its Oversight

Agency will treat lab-developed tests the same as other in vitro diagnostics

FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests - Vimarsana News

FDA Takes Action Aimed at Helping to Ensure the Safety and Effectiveness of Laboratory Developed Tests

Today, the U.S. Food and Drug Administration took action aimed at helping to ensure the safety and effectiveness of laboratory developed tests.

Source: fda.gov
UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence - Vimarsana News

UCLA and PreciseDx Announce New Collaboration to Advance AI-Enabled Predictions and Risk Mitigation for Triple-Negative Breast Cancer Recurrence

/PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven disease...

FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Healthcare - Vimarsana News

FDA's Proposed Rule For Oversight Of Laboratory Developed Tests: Part II: FDA's Proposed Phaseout Policy – Key Considerations & Open Questions - Healthcare

After an over decade-long discourse amongst interested stakeholders, on October 3, 2023, FDA unveiled its proposed rule and policy to increase oversight over LDTs.

Source: mondaq.com